Patents by Inventor Xiaozhao Wang

Xiaozhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROCYCLIC LACTAM INHIBITORS
    Publication number: 20250101020
    Abstract: The present application provides bicyclic spriolactam compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: March 27, 2025
    Inventors: Stacey Shepard, Lixin Shao, Xiaozhao Wang, Eddy W. Yue
  • BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS
    Publication number: 20250084087
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I), and pharmaceutical compositions of the same, that are modulators, antagonists, or inhibitors of the G protein-coupled receptor MRGPRX2 and are useful in the treatment of MRGPRX2 dependent conditions such as inflammatory diseases.
    Type: Application
    Filed: August 16, 2024
    Publication date: March 13, 2025
    Inventors: Oleg Vechorkin, Dipendu Das, Yong Li, Heeoon Han, Minh Nguyen, Robert Swyka, Hai Fen Ye, Hunter Sims, Xiaozhao Wang, Monika Scuron, Kai Liu
  • BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS
    Publication number: 20250084063
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I), and pharmaceutical compositions of the same, that are modulators, antagonists, or inhibitors of the G protein-coupled receptor MRGPRX2 and are useful in the treatment of MRGPRX2 dependent conditions such as inflammatory diseases.
    Type: Application
    Filed: August 16, 2024
    Publication date: March 13, 2025
    Inventors: Oleg Vechorkin, Dipendu Das, Yong Li, Heeoon Han, Minh Nguyen, Hai Fen Ye, Xiaozhao Wang, Kai Liu, Monika Scuron, Haisheng Wang
  • Bicyclic DGK Inhibitors
    Publication number: 20250066363
    Abstract: The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 23, 2024
    Publication date: February 27, 2025
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Ding-Quan Qian, Xiaozhao Wang, Bo Wei
  • CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY
    Publication number: 20250059293
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: July 10, 2024
    Publication date: February 20, 2025
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
    Publication number: 20250041310
    Abstract: The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
    Type: Application
    Filed: July 10, 2024
    Publication date: February 6, 2025
    Inventors: Hui Wang, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Chao Qi, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Wenyu Zhu
  • TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20250034153
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 27, 2024
    Publication date: January 30, 2025
    Inventors: Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20240415840
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: June 7, 2024
    Publication date: December 19, 2024
    Inventors: Joshua Hummel, Ding-Quan Qian, Xiaozhao Wang, Ming Xiang, Meizhong Xu
  • PYRAZOLOQUINOLINE KRAS INHIBITORS
    Publication number: 20240400557
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: May 28, 2024
    Publication date: December 5, 2024
    Inventors: Wenyu ZHU, Xiaozhao Wang, Wenqing Yao
  • PYRROLIDINE KRAS INHIBITORS
    Publication number: 20240390340
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 17, 2024
    Publication date: November 28, 2024
    Inventors: Onur ATASOYLU, Peter Carlsen, Suman Chakrabarty, Bin Hu, Chengtsung Lai, Chunyin Marshall Law, Gencheng Li, Matthew McCammant, Rocco Policarpo, III, Ken Mukai, Alexander Sokolsky, Xiaozhao Wang, Fenglei Zhang, Robert Susick
  • 2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS
    Publication number: 20240368156
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 18, 2024
    Publication date: November 7, 2024
    Inventors: Onur ATASOYLU, Peter Carlsen, Lei Liu, Matthew McCammant, Rocco Policarpo, III, Alexander Sokolsky, Xiaozhao Wang, Haolin Yin, Chengtsung Lai
  • QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20240368152
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: February 9, 2024
    Publication date: November 7, 2024
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20240360140
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 31, 2024
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • CYCLIC UREA KRAS INHIBITORS
    Publication number: 20240358702
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 17, 2024
    Publication date: October 31, 2024
    Inventors: Onur ATASOYLU, Peter Carlsen, Bin HU, Chengtsung Lai, Matthew McCammant, Alexander Sokolsky, Xiaozhao Wang
  • VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20240343742
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 23, 2024
    Publication date: October 17, 2024
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
  • Bicyclic Ureas As Kinase Inhibitors
    Publication number: 20240317744
    Abstract: The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: March 12, 2024
    Publication date: September 26, 2024
    Inventors: Xin Li, Oleg Vechorkin, Yanran Ai, Onur Atasoylu, Hang Thi Dang, Brent Douty, Chunhong He, Peng He, Michael Liang, Minh Nguyen, Evan Styduhar, Anlai Wang, Xiaozhao Wang, Hai Fen Ye, Eddy W. Yue, Ke Zhang, Peng Zhao
  • Imidazole and triazole KRAS inhibitors
    Patent number: 12077539
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: September 3, 2024
    Assignee: Incyte Corporation
    Inventors: Chao Qi, Xiaozhao Wang, Wenqing Yao
  • Heteroaryl Fluoroalkenes As DGK Inhibitors
    Publication number: 20240270739
    Abstract: The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: November 17, 2023
    Publication date: August 15, 2024
    Inventors: Ming Xiang, Joshua Hummel, Shaoqun Qian, Shicheng Shi, Xiaozhao Wang
  • CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
    Patent number: 12060433
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: August 13, 2024
    Assignee: Incyte Corporation
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • Hetero-tricyclic compounds as inhibitors of KRAS
    Patent number: 12030883
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu